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PD 404,182 (PD) is a synthetic compound that was found to compromise HIV integrity via interaction with a nonenvelope pro-
tein viral structural component (A. M. Chamoun et al., Antimicrob. Agents Chemother. 56:672– 681, 2012). The present study
evaluates the potential of PD as an anti-HIV microbicide and establishes PD’s virucidal activity toward another pathogen, herpes
simplex virus (HSV). We show that the anti-HIV-1 50% inhibitory concentration (IC50) of PD, when diluted in seminal plasma,
is1M, similar to the IC50 determined in cell culture growth medium, and that PD retains full anti-HIV-1 activity after incu-
bation in cervical fluid at 37°C for at least 24 h. In addition, PD is nontoxic toward vaginal commensal Lactobacillus species (50%
cytotoxic concentration [CC50],>300M), freshly activated human peripheral blood mononuclear cells (CC50,200M), and
primary CD4 T cells, macrophages, and dendritic cells (CC50,>300M). PD also exhibited high stability in pH-adjusted Dul-
becco’s phosphate-buffered saline with little to no activity loss after 8 weeks at pH 4 and 42°C, indicating suitability for formula-
tion for transportation and storage in developing countries. Finally, for the first time, we show that PD inactivates herpes sim-
plex virus 1 (HSV-1) and HSV-2 at submicromolar concentrations. Due to the prevalence of HSV infection, the ability of PD to
inactivate HSV may provide an additional incentive for use as a microbicide. The ability of PD to inactivate both HIV-1 and
HSV, combined with its low toxicity and high stability, warrants additional studies for the evaluation of PD’s microbicidal can-
didacy in animals and humans.
Since its discovery in humans in 1981, human immunodefi-ciency virus (HIV), the causative agent of AIDS, has infected
over 60 million people worldwide and caused more than 25 mil-
lion deaths (1). Although highly active antiretroviral therapy
(HAART) can significantly reduce the viral load and prolong pa-
tients’ life expectancy, these therapies are not curative (2).World-
wide, nearly half of all individuals living with HIV are women,
most of whomacquire the virus after sexual intercoursewithHIV-
positive men. As receptive partners, women are twice as likely as
theirmale counterparts to acquireHIV during sex (3). Despite the
knowledge of effective prevention strategies, such as the ABC ap-
proach (abstinence, be faithful, and use of condoms), the rate of
HIV transmission remains high in developing countries (4).
Moreover, many women cannot reliably negotiate safe sex prac-
tices, leaving them vulnerable to sexually transmitted infections.
Thus, the development of a safe, effective, and acceptable topical
microbicide capable of retarding or preventing the sexual trans-
mission of HIV could empower women to take personal re-
sponsibility to prevent HIV acquisition from their infected
partners (5).
Topical microbicides are agents able to inhibit the transmis-
sion of viral infections when applied to the vagina, penis, and/or
lower gastrointestinal (GI) tract via the rectum. An ideal anti-HIV
microbicide should fulfill most or all of the following criteria: (i)
inhibit transmission of wild-type and drug-resistant virus (6); (ii)
be stable and potent in seminal fluids and vaginal secretions; (iii)
lack toxicity to the vaginal epithelium and commensal bacterial
flora; (iv) be able to interfere with multiple transmission modes
(e.g., as cell-free virus versus cell-associated virus), given the un-
knowns in the exactmode of HIV transmission in vivo; (v) possess
a high genetic barrier to resistance development; (vi) preferably
act through a mode of action distinct from the modes of action of
existing therapeutics (7); and (vii) lack proinflammatory activity
and immunotoxicity. The last consideration derives from the
presence of rare preexisting drug-resistant viral variants, as well as
drug-resistant HIV variants, from patients who underwent previ-
ous antiretroviral treatment that can bypass the microbicidal bar-
rier and transmit to target cells. Most current anti-HIV microbi-
cide candidates in clinical trials are formulated on the basis of
existing antiretroviral drugs and target well-studied viral proteins
such as HIV protease (PR), reverse transcriptase, and HIV enve-
lope protein (Env) (6–10). In the CAPRISA 004 clinical trial in-
volving 1% tenofovir gel, HIV type 1 (HIV-1) acquisition was
reduced by38% in all woman and by 54% in woman who used
the gel 80% or more of the time (11). Interestingly and unexpect-
edly, in the same trial, tenofovir gel was found to also inhibit
HSV-2 acquisition by 51% (11). The recently FDA-approved anti-
HIV prophylactic therapeutic Truvada comprises two nucleoside
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analogs, tenofovir and emtricitabine (12). Truvada offered a 44%
reduction in HIV transmission during initial clinical trials (12).
However, since both tenofovir and emtricitabine are currently
used in the clinic for HIV treatment as part of a HAART drug
cocktail, concerns were raised about the potential for the spread of
drug-resistant variants when the drug is used by individuals with
unknown or positive HIV status. This issue becomes more signif-
icant when the drug is used on a large scale, generating an extra
incentive to identify new and specific anti-HIVmicrobicidal com-
pounds with uniquemodes of action. In addition, a recently com-
pleted comprehensive HIV prevention trial among African
women known as VOICE (Vaginal and Oral Interventions to
Control the Epidemic) involving tenofovir failed to provide
protection against HIV, underscoring the need for additional
HIV prevention options that incentivize patient usage and ad-
herence (6).
Recently, our laboratory discovered a synthetic smallmolecule,
PD 404,182 (PD), that possesses virucidal activity toward retrovi-
ruses, including HIV (13). PD is structurally and mechanistically
distinct from existingHIVmicrobicides (6, 7) and inhibits a broad
range of primary isolates of HIV and simian immunodeficiency
virus (SIV) at submicromolar to micromolar concentrations with
minimal cytotoxicity to human cells (50% cytotoxic concentra-
tion [CC50]/50% inhibitory concentration [IC50], 300). Previ-
ously, we found that PD (i) is effective against a broad range of
primaryHIV-1 isolates aswell asHIV-2 (IC50,1M) inTZM-bl
cells; (ii) is fully active in cervical fluids; (iii) exhibits low toxicity
in 7 different human cell lines, including cervical cancer cells
(CC50,300 M); (iv) is effective against both cell-free and cell-
associated virus and inhibits the transmission of dendritic cell-
associated HIV to T cells; (v) retains antiviral potency in cell cul-
ture for at least 8 h prior to the addition ofHIV to the cells; and (vi)
exhibits rapid antiviral action (HIV becomes 99% inactivated
after a 5-min incubation with PD) (13).
In this study, we further evaluated the potential of PD as an
anti-HIV microbicide and show that PD (vii) is stable and effec-
tive at both acidic and neutral pH for at least 48 h, (viii) remains
fully active in the presence of seminal plasma and after incubation
in cervical fluids for at least 24 h, (ix) retains full potency when
stored in Dulbecco’s phosphate-buffered saline (DPBS) under
acidic pH at 42°C for at least 8 weeks, (x) can be formulated in
hydroxyethyl cellulose (HEC) gel under acidic conditions, (xi) is
nontoxic to the vaginal commensal bacterium Lactobacillus
(CC50, 300 M) and freshly activated peripheral blood mono-
nuclear cells (PBMCs; CC50,200 M), (xii) is active in PBMCs
against HIV-1 clinical isolates representing different viral sub-
types and tropisms (average IC50 0.55 M), and (xiii) does not
foster the emergence of resistant variants when HIV-1-positive
TZM-bl cells are passaged at subinhibitory concentrations of PD
in cell culture for 60 days. Finally, we show that PD effectively
inactivates human herpes simplex virus 1 (HSV-1) and HSV-2 at
submicromolar concentrations (200 nM). In the United States
alone, 16.2% of the population is estimated to be infected with
HSV-2 (15). InfectionwithHSV-1 or -2 is an important risk factor
for susceptibility to HIV-1 transmission in vitro (16). These new
findings further underscore PD as a promising newHIVmicrobi-
cide. In addition, PD is a small molecule that can be easily synthe-
sized (17) and thus can potentially bemanufactured at low cost on
a large scale for use in developing countries.
MATERIALS AND METHODS
Cells, media, and reagents. PD 404,182 was purchased from Sigma-Al-
drich (St. Louis,MO). PDwas dissolved in dimethyl sulfoxide (DMSO) to
a final concentration of 30 to 40 mM, aliquoted, and stored at 20°C.
DPBS and penicillin-streptomycin (pen-strep) were purchased from
Thermo Scientific HyClone (Logan, UT) and Lonza (Walkersville, MD),
respectively. Unless otherwise stated, the complete growthmedium for all
cell culture work was Dulbecco modified Eagle medium (DMEM) con-
taining 4,500 mg/liter glucose, 4.0 mM L-glutamine, and 110 mg/liter
sodiumpyruvate (Thermo ScientificHyClone, Logan, UT) supplemented
with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and
1 nonessential amino acids (Thermo Scientific HyClone, Logan, UT).
293T cells were from Life Technologies (Grand Island, NY). Vero cells
were obtained from ATCC (Manassas, VA). The following reagents were
obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH: TZM-bl from John C. Kappes, XiaoyunWu, and Tranzyme
Inc.; HIV-1 isolates 92RW016, 92RW021, 92TH006, 92TH026, 93TH053,
93BR020, 93BR021, 93BR029, 98IN017, 98IN022, 92UG001, 92UG005,
92UG024, and 92UG029 from The UNAIDS Network for HIV Isolation
and Characterization (18); HIV-1 92HT599 from Neal Halsey; HIV-1
96USNG31 from D. Ellenberger, P. Sullivan, and R.B. Lal (19); HIV-1
RU132 fromA. Bobkov and JonathonWeber; HIV-1 93IN101 from Rob-
ert Bollinger; and HIV-1 Jv1083 from Alash’le Abimiku (20). All primary
HIV isolates were amplified in activated human PBMCs. HIV NL4-3 was
obtained from the NIH AIDS Research and Reference Program. HSV-1
(strain Syn 17) andHSV-2 (strain 333) were obtained fromTheoGeijten-
beek (21) and amplified, and titers were determined in Vero cells.
Lentiviral pseudoparticle production.Pseudotyped lentiviruses were
produced by cotransfecting 293T cells with plasmids carryingHIV gag-pol
(22), a provirus (pV1-B1 [13], pTRIP-Gluc [23], or NL4-3.Luc [NIH
AIDS Reagent Program]), and vesicular stomatitis virus glycoprotein
(VSV-G) (22). TransIT reagent (Mirus, Madison, WI) was used to per-
form the transfection following the manufacturer’s protocol. The super-
natants containing the pseudoparticles were collected at 48 h posttrans-
fection, filtered (0.45-m pore size), and stored at80°C until use.
PD stability. As a gauge of compound stability, we determined the
antiviral activity of PD after storage under different conditions for differ-
ent periods of time. PD was diluted in buffered DPBS (pH 4, 6, 8, 10) or
cervical fluids (a pool of fluids from 3 donors 5-fold diluted in DPBS; Lee
Biosolutions, St. Louis, MO) to achieve a final concentration of 30 M.
DPBS was buffered to the desired pH using hydrochloric acid or sodium
hydroxide. Diluted drugwas incubated at the desired temperature for 0, 8,
24, or 48 h. After the temperature incubation, the drug mixture was fur-
ther diluted to 1, 0.1, and 0.05 M in complete growth medium and used
for incubation with VSV-G lentiviral pseudoparticles (VSV-Gpp; harbor-
ing either pTRIP-Gluc or NL4-3.Luc viral supernatant diluted 500-fold in
complete growth medium) at 37°C for 30 min. Huh-7.5 cells (2  104
cells/well) or 293T cells that had been seeded 24 h earlier were inoculated
with the PD-treated virus at 4°C for 2 h, thoroughly washed to remove
unbound viruses and drug, replenished with complete growth medium
containing 1 pen-strep, and returned to 37°C in 5% CO2. Viral infec-
tivity was quantified 48 h later by measuring supernatant Gaussia lucifer-
ase (Gluc) levels using a BioLuxGaussia luciferase assay kit (New England
BioLabs, Ipswich, MA) or a firefly luciferase assay kit.
To study the long-term stability of PD, the compoundwas diluted to 5
M in DPBS buffered at pH 4 and 7 using acetic acid (0.1%) and HEPES
(2.5 mM), respectively, aliquoted, and incubated at 4°C, room tempera-
ture (RT), or 42°C. Each week an aliquot was removed and tested for
antiviral activity as previously described above. Similar experiments were
conducted with PD (5 M) or vehicle control (0.02% DMSO) diluted in
DPBS (adjusted to pH 4) containing 1.5% HEC.
PD stability in seminal plasma. TZM-bl cells (105 cells/well, 50 l)
were seeded in a flat-bottom 96-well plate. On the next day, PD dilutions
were prepared at a 2 concentration in seminal plasma (pooled from 10
HIV-seronegative donors [Lee Biosolutions] 2-fold diluted in DMEM),
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and 100 l of the 2-concentrated mixtures was added to the wells. Fifty
microliters of a predetermined dilution of HIV stock (X4 NL4-3, 1 ng of
p24, also in 50% seminal plasma)was placed in each test well. The cultures
were incubated at 37°C in 5% CO2 for 4 h and washed with complete
growthmedium to remove unbound viruses and compound, fresh growth
medium was replaced, and the cultures were returned to the incubator.
Infection was scored 48 h later by -galactosidase activity.
Anti-HIV efficacy evaluation in fresh human PBMCs. Testing of the
efficacy of PD againstHIV-1 in PBMCs (Biological Specialty Corporation,
Colmar, PA) was performed at the Southern Research Institute as de-
scribed previously (24, 25). Briefly, phytohemagglutinin-stimulated cells
from at least two healthy donors were mixed together, diluted in fresh
medium to a final concentration of 1  106 cells/ml, and plated in a
96-well round-bottom microplate at 50 l/well (5 104 cells/well). Test
drug dilutions were prepared at a 2 concentration in microtiter tubes,
and 100 l of the 2-concentrated mixtures was added to the wells. Fifty
microliters of a predetermined dilution of virus stock was placed in each
test well (finalmultiplicity of infection [MOI],0.1). Separate plateswere
prepared identically without virus for drug cytotoxicity studies. The
PBMC cultures were maintained for 7 days following infection at 37°C in
5% CO2. After this period, cell-free supernatant samples were collected
for analysis of reverse transcriptase activity (26), and compound cytotox-
icity was measured by addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; CellTiter
96 reagent; Promega) to the separate cytotoxicity plates for determination
of cell viability. Wells were also examined microscopically, and any ab-
normalities were noted.
Lactobacillus toxicity testing. Reference strains of Lactobacillus
crispatus and L. jensenii were obtained from ATCC (Manassas, VA) and
cultured on Columbia blood agar plates at 35°C in air enriched with 6%
CO2. Bacterial suspensions were prepared in saline or ACES buffer (27) to
a density of 2McFarland units (2 108 bacteria/ml) and exposed to PD
(300 M) or DMSO (10%) for 30 min at 37°C. After incubation, the cells
were serially diluted in ACES buffer, pH 7.0 (Sigma-Aldrich, St. Louis,
MO), and plated on blood agar plates to quantify the number of CFU per
ml (27).
Primary cell toxicity testing. Primary cells were seeded at 6  103
cells/well in flat-bottom 96-well plates in triplicate in the presence of
increasing concentrations of PD. We used the permeabilization agent sa-
ponin (0.1%) as a positive control. After 0, 7, and 14 days, the amounts of
lactate dehydrogenase (LDH) in the cell culture medium were quantified
using an LDH cytotoxicity assay kit (Cayman Chemical, Ann Arbor, MI).
Cell death can occur either by apoptosis or by necrosis. Necrosis is
accompanied bymitochondrial swelling and increased plasmamembrane
permeability, whereas apoptosis involves an articulated breakdown of the
cell into membrane-bound apoptotic bodies. LDH is a soluble cytosolic
enzyme that is released into the culture medium following the loss of
membrane integrity resulting from either apoptosis or necrosis. LDH ac-
tivity, therefore, can be used as an indicator of cell membrane integrity
and serves as a general means to assess cytotoxicity resulting from chem-
ical compounds or environmental toxic factors. Cayman’s LDH cytotox-
icity assay kit measures the LDH activity present in the culture medium
using a coupled two-step reaction. In the first step, LDH catalyzes the
reduction of NAD	 toNADHandH	 by oxidation of lactate to pyruvate.
In the second step of the reaction, diaphorase uses the newly formed
NADH andH	 to catalyze the reduction of a tetrazolium salt [2-(4-iodo-
phenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride] to highly col-
ored formazan, which absorbs strongly at 490 to 520 nm.
HSV infection assays. Vero cells (2 105 cells/well) were seeded in a
24-well plate. On the next day, these cells were infected with increasing
titers (MOI range, 0.0001 to 1) of HSV-1 (strain Syn 17) or HSV-2 (strain
333) in the presence of PD (2Mand 200 nM) orDMSO (0.01%) control
prepared in DMEM in the absence of serum. At 2 days postinoculation,
cells were harvested, fixed with 5% paraformaldehyde (PFA) in phos-
phate-buffered saline (PBS), stained with antibodies against HSV glyco-
protein gD (Novus Biological, Littleton, CO), and analyzed by flow
cytometry (21).
HSV sedimentation assay. HSV was concentrated by loading 30 ml
HSV-1-infected Vero cell supernatant on a 20% sucrose cushion and cen-
trifuging in an SW 28 rotor at 20,000 rpm for 1 h at 4°C. Pelleted viruses
(20 g/ml) were resuspended in 1 ml PBS, exposed to PD (200 nM) or
DMSO (0.01%) for 30 min at 37°C, and immediately loaded over a 20 to
70% sucrose density gradient (11 ml). After ultracentrifugation at 30,000
rpm for 24 h in an SW 41 T rotor at 4°C, fractions of 1 ml were collected
and analyzed for HSV gB content by enzyme-linked immunosorbent as-
say (ELISA) using homemade rabbit polyclonal antibody. The density of
each fraction from the sucrose gradient was determined bymeasuring the
refractive index.
Statistical analysis. Statistical significance between different samples
was evaluated using a two-tailed Student’s t test in the Microsoft Excel
program. A P value of 0.05 was considered statistically significant.
RESULTS
Efficacy of PD in seminal plasma. Previously, we showed that PD
effectively inhibits several isolates of HIV-1 and SIV in TZM-bl
cells at submicromolar to low micromolar concentrations (IC50,
1M)when diluted in DMEMor cervical fluid (13). It has been
shown that seminal plasma can enhance HIV infectivity (28, 29)
and protect HIV against the action of microbicides (30–32). We
therefore sought to test the antiviral activity of PD in seminal
fluids. Briefly, CD4	 CCR5	 HeLa cells (TZM-bl cells [33–37])
that produce -galactosidase in response to HIV infection were
exposed to 14 different clinical and laboratory isolates of HIV-1,
representing various subtypes that use either coreceptor CCR5
(R5 viruses) or coreceptor CXCR4 (X4 viruses), in the presence of
PD or DMSO prepared in 50% seminal plasma. After 4 h of incu-
bation of the virus and compoundwith the cells, cells were washed
and the infection was scored 48 h later by -galactosidase activity.
The IC50 and IC90 of PD against the tested subtypes of HIV-1
ranged from 0.42 to 1.96 M and 1.58 to 7.19 M, respectively
(Table 1). These values are consistent with those of PD’s anti-HIV
activity determined inDMEM(0.33 to 1.80Mfor IC50 and 1.4 to
6.6Mfor IC90) and in cervical fluid (0.61 to 2.30Mfor IC50 and
1.80 to 7.50 M for IC90) (13), indicating that seminal plasma
does not negatively impact PD’s anti-HIV activity.
TABLE 1 PD’s anti-HIV efficacy in seminal plasmaa
HIV isolate Clade Coreceptor usage IC50 (M) IC90 (M)
92RW021 A R5 0.58
 0.04 4.62
 0.32
92UG029 A X4 1.33
 0.02 4.71
 0.26
92TH026 B R5 0.43
 0.02 2.95
 0.18
92HT599 B X4 1.93
 0.03 6.31
 0.52
93IN101 C R5 1.76
 0.02 5.36
 0.37
98IN017 C X4 0.45
 0.05 2.09
 0.19
92UG005 D R5 1.32
 0.02 5.57
 0.44
92UG024 D X4 0.42
 0.03 1.58
 0.20
92TH006 E R5 1.96
 0.01 6.73
 0.51
93TH053 E X4 1.67
 0.02 5.56
 0.48
93BR029 F R5 0.85
 0.01 3.72
 0.26
93BR020 F X4 1.61
 0.02 7.19
 0.62
RU132 G R5 0.74
 0.01 3.28
 0.22
Jv1083 G R5 1.27
 0.01 4.22
 0.39
a TZM-bl cells (1 105 cells/ml) were exposed to the indicated HIV isolates (1 ng of
p24) in the presence of PD or DMSO diluted in 50% seminal plasma. Cells were washed
at 4 h postinoculation, and fresh growth medium was added. Infection was scored 48 h
later by -galactosidase activity. Values and errors represent the means and standard
deviations, respectively, of 2 independent experiments carried out in duplicate.
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Efficacy and toxicity of PD evaluated using primary cells.We
previously evaluated the cytotoxicity of PD on 7 different human
cell lines, including TZM-bl (HeLa) human cervical cells (13). In
all cases, PD showedminimal cytotoxicity (CC50,300M), giv-
ing a therapeutic index (CC50/IC50) of 300 for HIV-1. In the
current study, freshly activated human PBMCs pooled frommul-
tiple donors were infectedwith 8HIV-1 clinical isolates represent-
ing different viral subtypes and tropisms in the presence of differ-
ent concentrations of PD. The supernatant reverse transcriptase
activity was determined 7 days later and used as an indication of
HIV infection. The toxicity of PDwas determined under identical
conditions in the absence of HIV infection and replication. As
shown in Table 2, PD exhibited antiviral activity toward all the
viral isolates tested, with an average IC50 of 0.55 M (IC50 range,
0.14 M with HIV-1 96USNG31 to 1.18 M with HIV-1
92UG029). A 48% reduction in cell viability was observed at the
highest tested PD concentration (200 M), resulting in a CC50 of
200 M, indicating that PD is relatively nontoxic to freshly ac-
tivated human PBMCs. The therapeutic index of PD ranged from
170 (for HIV-1 92USNG31) to 1,425 (for HIV-1 96USNG31).
To evaluate the toxicity of PD against other primary cells, in-
creasing concentrations of PD were incubated with CD4	 T lym-
phocytes, macrophages, and dendritic cells for up to 14 days. As
shown in Fig. 1, minimum toxicity was observed in all three types
of primary cells (CC50s, 300 M), further pointing to the ex-
tremely low cytotoxicity of PD. We also conducted an 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide as-
say on these primary cells 7 days after PD exposure (200 M) and
did not observe any significant cytotoxic effect (data not shown).
Toxicity of PD toLactobacillusnormal vaginal flora.Thevag-
inalmicroflora is a key component of the innate immune environ-
ment and plays an important role in reducing the risk of HIV
infection (38–41). The dominant bacterial species in healthy
woman is Lactobacillus, which produces lactic acid, hydrogen per-
oxide, bacteriocins, and other antimicrobial substances that in-
hibit the growth of pathogenic organisms in the vagina (38–42).
PD was evaluated for toxicity toward three strains of Lactobacillus
normally found in the vagina. These strains were incubated with
300 M PD or the solvent DMSO (10%) at 37°C for 30 min and
plated on blood agar plates to quantify the number of CFUperml.
A less than 1-log-unit difference between the control and test
numbers of CFU is considered nontoxic (27). As shown inTable 3,
no growth inhibition of any of the strains of bacteria was observed
after incubation with PD at a concentration of 300M, indicating
that PD is nontoxic to commensal Lactobacillus species.
PD short-term stability. We sought to determine the short-
term stability of PD under conditions that the compound is likely
to encounter if used as a microbicide by measuring its antiviral
activity at different times. The environment of the vagina is highly
TABLE 2 Toxicity and efficacy of PD in PBMCsa
HIV isolate Clade
Coreceptor
usage
IC50
(M)
IC90
(M)
Therapeutic
index
92RW016 A R5 0.22 0.54 916
92UG029 A X4 1.18 4.67 170
92HT599 B X4 0.55 1.92 364
93BR021 B R5 0.6 4.26 334
96USNG31 C X4/R5 0.14 1.62 1,425
98IN022 C R5 0.4 1.48 506
92UG001 D X4/R5 1.11 1.89 181
RU132 G R5 0.2 0.53 1,015
a The CC50 was200 M for all isolates. Freshly activated PBMCs (5 10
4 cells/well)
were infected with HIV isolates (MOI 0.1) in the presence of different concentrations
of PD. At 7 days after infection, supernatants were collected and analyzed for reverse
transcriptase activity. Compound toxicity was determined using an MTS assay in the
parallel uninfected plates. Values represent the means of triplicate samples from one
experiment using zidovudine as the positive control (data not shown).
FIG 1 PD exhibits minimum toxicity against primary human cells. Increasing concentrations were incubated with primary CD4	T lymphocytes, macrophages,
and dendritic cells at 37°C, and the amounts of lactate dehydrogenase (LDH) present in the culture medium were quantified after 0, 7, and 14 days. Values and
error bars represent the mean and standard deviation, respectively, from two independent experiments.
TABLE 3 Toxicity of PD toward commensal Lactobacillus bacteriaa
Bacterial strain
No. of CFU (105)/ml
Log(control)
log(PD)Control PD
Lactobacillus crispatus ATCC
33197
75.8
 0.19 72.6
 0.55 0.019
Lactobacillus jensenii ATCC
25258
99.8
 5.72 75.3
 16.8 0.122
Lactobacillus jensenii LBP 28Ab 105
 7.2 100
 0.124 0.021
a Triplicate bacterial suspensions (2 108 bacteria/ml) were separately exposed to
PD (300 M) or 10% DMSO for 30 min at 37°C. After incubation, each suspension was
serially diluted and plated on blood agar plates to quantify the number of CFU per ml.
Values and errors represent the means and standard deviations, respectively, of
triplicate samples.
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acidic (pH 3.5 to 4.9) due to the lactic acid produced by the com-
mensal Lactobacillus bacteria (43). Exposure to seminal fluid (pH
7.2 to 8) (44) can raise the vaginal pH to 5.8 to 7.2 for several hours
(45). Thus, we determined the stability of PD under different pHs
at 37°C (Fig. 2A). To ensure that the loss of antiviral activity is not
masked by an excess of compound, three different concentrations
of PD were used, including two in the vicinity of the IC50. PD
retained full activity in acidic buffer at pH 4 and 6 at 37°C. Since
PD targets a nonenvelope protein HIV-1 structural component
(13), we used HIV-1 pseudotyped with VSV-G (VSV-Gpp) for
these studies because this virus is easy to generate to high titers and
can be handled in a biosafety level 2 environment. A basic pH of 8
or 10 was observed to compromise PD’s activity, but only after
extended exposure. For example, PD lost50% antiviral activity
after incubation in pH 10 buffer for 48 h and lost 20% activity
when exposed to pH 8 for 48 h at 37°C. In contrast, no activity loss
was observed for PD after 24 h of exposure to pH 8 buffer, and
minimal (20%) activity loss was seen after 24 h of exposure to
pH 10. Taken together, these results indicate that PD will likely be
stable in highly acidic cervical fluid and should remain active for at
least several hours upon contact with seminal fluid.
Since cervical fluid is a complex mixture, we next determined
the stability of PD in cervical fluid. As shown in Fig. 2B, no activity
loss was observed after PD was incubated in 20% cervical fluid for
24 h at 37°C. These results indicate that once-a-day application of
PD should be adequate to provide protection against HIV infec-
tion. The ability of PD to retain its antiviral potency at a nearly
neutral pH suggests that PDmay also be formulated as a rectal gel.
PD long-term stability. To evaluate long-term stability, PD
was diluted in DPBS buffered at pH 4 or 7 and incubated at 4°C,
room temperature, or 42°C. An aliquot was taken every week for
determination of antiviral activity. As shown in Fig. 3A, PD was
extremely stable when stored in pH 4 buffer and retained full
antiviral potency even after 8 weeks at 42°C. At pH 7, PD was
stable only at room temperature and 4°C. Storage at 42°C and pH
7 significantly compromised PD activity after 2 weeks.
We also determined the stability of PD formulated in HEC gel
at pH4, as PD is not stable in the presence ofHECgel at pH7 (data
FIG 2 PD is stable and fully active at acidic pH and in cervical fluid. PD (30 M) or DMSO (10%) was incubated at 37°C for 0, 8, 24, or 48 h in DPBS adjusted
to pH 4, 6, 8, or 10 (A) or 20% cervical fluid (the diluent was DPBS) (B). These PD samples were then diluted to the desired concentration in complete growth
medium containing VSV-Gpp (viral supernatant diluted 500-fold), and the PD-virus mixtures were incubated at 37°C for 30 min and used to inoculate naive
Huh-7.5 or 293T cells at 4°C for 2 h prior to incubation at 37°C in 5% CO2. The infectivity (virus entry into cells) was quantified by measuring the supernatant
luciferase reporter activity at 48 h postinfection. Values and error bars represent the means and standard deviations, respectively, of at least two independent
experiments carried out in duplicate. Statistical significance was determined by Student’s t test (*, P 0.01).
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not shown). PD retained full potency at pH 4 in 1.5% HEC gel at
4°C andRT for at least 4 weeks. However, PDwas not stable under
the same buffer conditions if stored at 42°C (Fig. 3B) for more
than 2 weeks, despite its stability in pH 4 DPBS buffer. Work is
under way to determine other suitable formulation conditions for
PD storage at high temperatures.
HIV-1 does not acquire resistance to PD after 60 days. With
the high rate of HIVmutation, an ideal microbicide should have a
high threshold for viral resistance development. To gauge the abil-
ity of HIV-1 to acquire resistance to PD, TZM-bl cells were in-
fected with HIV-1 at an estimated MOI of 0.001 to 0.005 and
passaged in the presence of 1, 5, and 10 M PD for 60 days. A
similar method was previously employed to successfully evolve
HIV-1 resistance againstmultipleHIV protease/reverse transcrip-
tase inhibitors (46–48) and in resistance evolution of other viruses
(49–53). For a classical HIV-1 protease and reverse transcriptase
inhibitor with a known mechanism, the supernatant capsid p24
level is usually undetectable for the first 1 to 2 weeks but increases
to 1 to 50 ng/ml after 4 weeks. No detectable p24 was measured in
the supernatant even after 60 days (see Fig. S1 in the supplemental
material), suggesting that no PD-resistant variants evolved during
this time frame and also suggesting that PD has a high resistance
barrier. The inability of HIV-1 to escape PD inactivation further
underscores the potential of PD as an HIV-1 microbicide. We
chose TZM-bl cells for the resistance study because these cells can
be passaged for an extended period and remain viable for months
even in the presence of viral replication. A similar experiment was
performed using freshly activated human PBMCs (from two do-
nors), and no emergence of viral resistance was observed (data no
shown). However, HIV-1-infected PBMCs were cultured for only
12 days because significant cell death was observed after this pe-
riod. We also cultured HSV-1-infected Vero cells in the presence
of subinhibitory concentrations of PD for 2 weeks and were not
able to detect any viral capsid by ELISA in the supernatant (data
not shown).
PD inactivates HSV-1 and HSV-2. We investigated the ability
of PD to inactivate HSV-1 and HSV-2. Vero cells were infected
with HSV-1 andHSV-2 in the presence of PD (2Mand 0.2M)
or DMSO (0.01%). These concentrations were selected on the
basis of their closeness to the in vitro IC50 of PD against HIV-1.
Infection was quantified by the cell surface expression of HSV gD.
PD was found to inhibit both HSV-1 and HSV-2 infection at low
to intermediate MOIs (MOI range, 0.0001 to 0.1) and exhibited
partial protection at an MOI of 1 (Fig. 4A). The data from the
lowest concentration are presented. At 2 M, similar results were
obtained, except that the protection curve shifted to the right,
leading to full protection at an MOI of 1 and partial protection at
an MOI of 10.
Previously, we showed that PD compromises the integrity of
retroviruses (13). We thus asked whether PD can disrupt the
FIG 3 Long-term stability of PD. PD (5M) or DMSO (1.67%) was diluted in pH-adjusted DPBS (pH 4 or 7) (A) or 1.5%HEC in DPBS (pH 4) (B) and stored
at the indicated temperature for 8 weeks. An aliquot was removed each week, diluted to the desired concentration in complete growth medium containing
VSV-Gpp (500-fold diluted), incubated at 37°C for 30min, and used to infect naive Huh-7.5 cells at 4°C for 2 h prior to incubation at 37°C in 5%CO2. The viral
infectivity was quantified by measuring the supernatant Gluc reporter activity at 48 h postinfection. Values and error bars represent the means and standard
deviations, respectively, of duplicate samples. Statistical significance was determined by Student’s t test (*, P 0.05).
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692 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
structure of HSV virions. Purified HSV-1 virions were resus-
pended in PBS and incubated with PD (0.2 M) or DMSO
(0.01%) for 30min at 37°C. After the incubation, the mixture was
immediately loaded over a 20 to 70% sucrose density gradient and
centrifuged at 30,000 rpm in an SW 41 T rotor for 24 h. Each
gradient fractionwas analyzed forHSV glycoprotein gB by ELISA.
DMSO-treatedHSV-1 sediments at a density of 1.24 g/cm3. How-
ever, with PD-exposed HSV, all gB distributed to the top of the
gradient (Fig. 4B). This result indicates that, like with HIV-1, PD
inactivates HSV by compromising virion structural integrity.
DISCUSSION
Four major types of vaginal HIV microbicides have been devel-
oped with various degrees of clinical success: surfactants, entry
inhibitors, vaginal milieu protectors, and reverse transcriptase in-
hibitors (6). Surfactants nonspecifically disrupt membranes and
were the first molecules to enter clinical trials as candidate HIV
microbicides. However, these surfactants were found to be toxic
to the cervicovaginal mucosa and resulted in an increased rate of
HIV infection in phase III clinical trials (54, 55). Entry inhibitors
prevent HIV from binding to or entering cells and encompass a
wide range of molecules, including CCR5 inhibitors (56–58) and
fusion inhibitors (59, 60). Many polyanions have also been devel-
oped to inhibit HIV entry, and some have been extensively tested
in phase III trials, including PRO 2000 (61), cellulose sulfate (62),
and Carraguard (63). However, most of these candidates have
failed to show in vivo efficacy in preventing HIV transmission,
partly due to the complexity of themucosal environment aswell as
the interference of semen (32, 64). Vaginal milieu protectors are
designed to maintain or enhance the protective acidic pH of the
vaginal environment through the use of strong buffering agents,
such as Carbopol 974 (65), or genetically engineered lactobacilli
(66). An agent that is being considered for HIV microbicidal ap-
plications in clinical trials, tenofovir, is a nucleotide analogue that
inhibits the reverse transcriptase of HIV (12). A 1% tenofovir gel
applied before and after sexual intercoursewas 39%effective over-
all in preventing HIV infection in women and 54% effective
among highly adherent users of the gel (11). These data are en-
couraging but nevertheless show that the efficacy of tenofovir mi-
crobicidal therapy alone is limited.
In contrast to existing anti-HIV microbicidal candidates, PD
inactivates HIV via a novel mechanism. PD is the only nonsurfac-
tant small molecule reported to physically compromise the integ-
rity of HIV, thus rendering the extracellular virus noninfectious
FIG 4 PD is effective against HSV. (A) PD blocks HSV infection. Vero cells were seeded in a 24-well plate and infected with HSV-1 (strain Syn 17) or HSV-2
(strain 333). PD (200 nM) or DMSO (0.01%) control was added to the target cells immediately after viral inoculation. Two days later, the cells were harvested,
stained with antibody against HSV glycoprotein gD, and analyzed by flow cytometry. Error bars represent standard deviations of triplicate samples. Results are
representative of two independent experiments. (B) PD destabilizes HSV particles. Concentrated HSV (20 g/ml) was incubated with DMSO (0.01%) or PD
(200 nM) for 30 min at 37°C, and the mixture was immediately loaded over a 20 to 70% sucrose density gradient. The amount of HSV glycoprotein gB in each
fractionwas analyzed by ELISA. The sucrose gradient density of each fractionwas determined bymeasuring the refractive index. Results are representative of two
independent experiments. Values and error bars represent the means and standard deviations, respectively, of triplicate samples.
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(Table 1 and 2). In addition, PD exhibits low toxicity toward sev-
eral human cell lines (13), freshly activated PBMCs (Table 2),
primary CD4	 T lymphocytes, macrophages, and dendritic cells
(Fig. 1), and lactobacilli found in the normal vaginal flora (Table
3). It should be noted, nevertheless, that we have yet to test the
cytotoxicity of PD under conditions that mimic the high level of
basal inflammation typically seen in developing countries. For
example, it has been reported that increased levels of immune
activation were observed in the genital tract of healthy young
women from sub-Saharan Africa (67).
The antiviral potency of PD is not affected by the presence of
seminal plasma (Table 1)or exposure to cervical fluid at 37°C for 24h
(Fig. 2B), indicating the potential for a once-a-day application of PD
for HIV prophylaxis. The very high stability of PD in acidic pH at
both roomtemperature and42°Cand inneutral pHat roomtemper-
ature (Fig. 3A) indicates that PD can be easily formulated for conve-
nient transportation and storage in developing countries lacking re-
frigeration facilities. In the current study,we evaluated the stability of
PD when formulated in 1.5% HEC gel. Surprisingly, PD was not
stable when formulated in HEC gel at pH 7 (data not shown), al-
though PD formulated inHEC gel at pH 4 retained full potency after
4 weeks at ambient temperature (Fig. 3B). Studies are under way to
investigate the reason for PD’s instability in HEC gel at neutral pH.
One hypothesis that we are exploring is that PD reacts with the de-
protonated hydroxyl group in HEC.
Genital herpes has been found to increase the vulnerability to
HIV-1 infection by compromising the integrity of the mucosal bar-
rier (68–70). Most genital herpes is caused by HSV-2 infection, al-
though in some cases it can also be caused byHSV-1 (71–73). In one
study, 50 to 90% of HIV-1-infected patients tested seropositive for
HSV-2 (74), and HSV-2 infection was found to increase the rate of
HIV-1 acquisition by 3-fold (72). Due to the synergy between HIV
andHSV, a topical microbicide with dual action against both patho-
gens maymore effectively reduce HIV transmission.
In addition to being an HIV microbicide, PD could also inac-
tivate HSV at nanomolar concentrations. Genital herpes is one of
the most prevalent sexually transmitted diseases worldwide and
is the common cause of genital ulcers (75). Ulcerations can dis-
rupt themucosal barrier and abrogate the protective barrier func-
tion of the epithelium, allowing HIV-1 to reach the subepithelial
dendritic cells susceptible to HIV-1 infection (16) and increasing
the risk of HIV acquisition (76). Currently, there is no approved
vaccine for HSV, and therapeutic treatment for genital herpes in-
volves repeated dosing of antiviral drugs. Development of topical
microbicides that are effective against both HIV and HSV may
provide a more effective strategy to prevent HIV-1 infection/
transmission. We showed that 0.2 M PD physically compro-
mises the integrity of extracellular HSV and effectively blocks the
infection of bothHSV-1 and 2 in vitro, in amanner similar to PD’s
action on HIV-1 (Fig. 4).
In the past 5 years, several broad-spectrum antiviral com-
pounds have been discovered. For example, the rigid amphipathic
fusion inhibitors (RAFIs) (77, 78) and lysophosphatidylcholine
(79) inhibit virus-host fusion by inducing positivemembrane cur-
vature, while LJ001 compromises virion integrity by intercalating
into the viral lipid membrane (80). There are others, like the C5A
amphipathic peptide derived from HCV NS5A protein (81, 82)
and alkylated porphyrins (83), whose mechanisms of virucidal
action remain somewhat mysterious.
Finally, it is worth noting that a number of factors tend to raise
the vaginal pH. For example, the seminal plasma can raise the
vaginal pH to 7.2 to 8 after intercourse (44). Women diagnosed
with Trichomonas vaginalis infection or bacterial vaginosis (BV)
have vaginal pHs that range from 4 to 7 (84, 85). However, as
shown in Fig. 2, PD retains most of its potency at pH 8 for over 24
h at 37°C. Thus, PD should remain effective in preventing HIV/
HSV infection even in these individuals.
In summary, we demonstrated that the virucidal small mole-
cule PD possesses several attributes that lend support to its use as
amicrobicide for combatingHIV spread. These attributes include
full activity and high stability in the fluids and pHs encountered
physiologically, a lack of toxicity to freshly activated human
PBMCs and vaginal commensal bacteria, and activity toward an-
other virus—HSV—that exacerbates the pathogenicity of HIV.
Future studies will focus on (i) formulation of PD into a topical
form that promotes high PD activity and stability and (ii) evalua-
tion of the toxicity and efficacy of PD in animals and humans.
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